LifeWorks declares July 2022 cash dividend

TORONTO–(BUSINESS WIRE)–(TSX: LWRK) LifeWorks Inc. (the “Company” or “LifeWorks”) announced today a cash dividend of $0.065 per share for the month of July 2022, to be paid on August 15, 2022 to holders of record of shares of LWRK on July 29, 2022. LifeWorks designates this dividend to be an “eligible dividend” pursuant to subsection … [Read more…]

Preclinical Data Demonstrate Potential of Creative Bio-Peptides’ Multi-Chemokine Receptor Antagonist RAP-103 to Enhance Opioid Analgesia and Inhibit Opioid-derived Dependence, Withdrawal and Respiratory Depression

ROCKVILLE, Md.–(BUSINESS WIRE)–Creative Bio-Peptides, Inc, a preclinical-stage biotechnology company developing novel therapies to balance the innate immune system and promote regeneration of damaged neurons, today announced the publication of findings from a preclinical study showing that treatment with the multi-chemokine receptor antagonist oral peptide RAP-103 substantially reduced heroin self-administration and motivation to consume heroin. RAP-103 … [Read more…]

Agiliti Announces Second Quarter 2022 Earnings Release Date and Conference Call

MINNEAPOLIS–(BUSINESS WIRE)–Agiliti Inc. (NYSE: AGTI) (“Agiliti”) today announced that the company will release its second quarter results after the market close on Tuesday, August 9, 2022, to be followed by a conference call at 5 p.m. Eastern Time on the same day. The conference call can be accessed live over the phone by dialing 1-877-407-0792 … [Read more…]

Koneksa Appoints Dr. Maria C. Freire to Board of Directors

NEW YORK–(BUSINESS WIRE)–#BoardofDirectors—Koneksa, a healthcare technology company pioneering digital biomarkers, today announced the appointment of Maria C. Freire, Ph.D., to its Board of Directors. Dr. Freire is an accomplished executive and public health leader with a proven track record in enabling life sciences companies to maximize the potential of their technology platforms. “Koneksa is privileged … [Read more…]

Pillar Biosciences Announces U.S. Food and Drug Administration Acceptance of Premarket Approval (PMA) Supplement Application for Pan-cancer oncoReveal™ CDx

˗ PMA supplement will further expand oncoReveal™ Dx indication/label to include ability to detect additional eight cancer types ˗ Company continues to execute on its strategy to bring highly accurate and sensitive NGS cancer diagnostics to enable localized testing NATICK, Mass.–(BUSINESS WIRE)–Pillar Biosciences, the leader in Decision Medicine™, which develops and distributes next-generation sequencing (NGS) … [Read more…]

Tectonic Therapeutic Strengthens Leadership Team

BOSTON–(BUSINESS WIRE)–Tectonic Therapeutic, Inc. a pre-clinical stage biotechnology company transforming the discovery of novel GPCR-targeted therapies (G-Protein Coupled Receptors), today announced the promotion of Senior Vice President, Head of Research, Peter McNamara, PhD, to Chief Scientific Officer as well as the appointments of Barry Rubenstein as Senior Vice President, People and Culture and Washington Alves … [Read more…]

Avista Therapeutics Partners with Roche to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases

UPMC spinout advances novel viral vector technology PITTSBURGH–(BUSINESS WIRE)–Avista Therapeutics, which recently launched as a spinout of leading health system UPMC, aims to develop innovative gene therapies for rare ophthalmic conditions. The new company today announced a partnership with Roche to develop novel AAV gene therapy vectors for the eyes. The partnership aims to apply … [Read more…]

Hurdle Health and Blue Cross and Blue Shield of Minnesota Begin Partnership Focused on Culturally Responsive Mental Health Care

Brooklyn Center residents given greater holistic care access as part of five-year place-based partnership EAGAN, Minn.–(BUSINESS WIRE)–Hurdle Health today announced a partnership with Blue Cross and Blue Shield of Minnesota (Blue Cross) to provide free culturally responsive mental healthcare to residents of Brooklyn Center. Traditional forms of therapy are not designed with cultural humility in … [Read more…]

908 Devices to Report Second Quarter 2022 Financial Results on August 9, 2022

BOSTON–(BUSINESS WIRE)–908 Devices Inc., (Nasdaq: MASS) a pioneer of purpose-built handheld and desktop mass spec devices for chemical and biomolecular analysis, today announced it will report financial results for the second quarter 2022 before market open on Tuesday, August 9, 2022. Company management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time … [Read more…]

Biodesix to Report Second Quarter 2022 Financial Results on August 4, 2022

BOULDER, Colo.–(BUSINESS WIRE)–$BDSX #patientsfirst—Biodesix, Inc. (Nasdaq: BDSX), a leading data-driven diagnostic solutions company with a focus on lung disease, today announced that it will release financial results for the second quarter ended June 30, 2022 before the open of trading on Thursday, August 4. Biodesix’s management will host a conference call and webcast to discuss … [Read more…]